Close Menu

NEW YORK – A real-world observational study has shown that treatment with afatinib (Boehringer Ingelheim's Gilotrif) followed by osimertinib (AstraZeneca's Tagrisso) resulted in prolonged survival of almost four years for non-small cell lung cancer patients with EGFR Del19 and T790M mutations. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.